Your browser doesn't support javascript.
loading
IL-17A in diabetic kidney disease: protection or damage.
Tan, Hai-Bo; Zheng, Yan-Qiu; Zhuang, Yu-Pei.
Afiliação
  • Tan HB; Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, PR China. Electronic address: thb13265042784@163.com.
  • Zheng YQ; Pi-Wei Institute, Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510006, PR China.
  • Zhuang YP; Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
Int Immunopharmacol ; 108: 108707, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35344813
ABSTRACT
The effect of IL-17A in diabetic kidney disease (DKD) has received increasing attention. Interleukin (IL)-17A promotes renal inflammation and the progression of DKD, and IL-17A deficiency improves experimental DKD. However, recent studies have found that the effect of IL-17A on DKD is more complicated than the negative impact. IL-17A alleviates renal inflammation and fibrosis via regulating autophagy or the macrophage phenotype. Moreover, paradoxical expression of IL-17A has been reported in human DKD. This review focuses on how IL-17A affects the progression of DKD and the resulting opportunities and challenges.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-17 / Diabetes Mellitus / Nefropatias Diabéticas Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-17 / Diabetes Mellitus / Nefropatias Diabéticas Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article